Mounting evidence suggests that bone marrow–derived cells (BMDC) contribute to tumor growth, angiogenesis, and metastasis. In acute reactions to cancer therapy, several types of BMDCs are rapidly mobilized to home tumors. Although this host reaction to therapy can promote tumor regrowth, its contribution to metastasis has not been explored. To focus only on the effects of chemotherapy on the host, we studied non–tumor-bearing mice. Plasma from animals treated with the chemotherapy paclitaxel induced angiogenesis, migration, and invasion of tumor cells along with host cell colonization. Lesser effects were seen with the chemotherapy gemcitabine. Conditioned medium from BMDCs and plasma from chemotherapy-treated mice each promoted metastatic properties in tumor cells by inducing matrix metalloproteinase-9 (MMP9) and epithelial-to-mesenchymal transition. In mice in which Lewis lung carcinoma cells were injected intravenously, treatment with paclitaxel, but not gemcitabine or vehicle, accelerated metastases in a manner that could be blocked by an MMP9 inhibitor. Moreover, chimeric mice reconstituted with BMDC where MMP9 activity was attenuated did not support accelerated metastasis by carcinoma cells that were pretreated with chemotherapy before their introduction to host animals. Taken together, our findings illustrate how some chemotherapies can exert prometastatic effects that may confound treatment outcomes. Cancer Res; 71(22); 6986–96. ©2011 AACR.
For the last several years, antiangiogenic therapy has emerged as an additional treatment modality in clinical oncology for a number of malignancies that include colorectal (1), non–small cell lung (2), hepatocellular (3), and renal cell (4) cancers. However, the approval of antiangiogenic drugs by the U.S. Food and Drug Administration (FDA) has been limited because such drugs sometimes resulted in increased progression-free, but not overall, survival of patients with certain tumors, for example, advanced metastatic breast cancer (5). Therefore, doubts have been raised with respect to the overall efficacy of antiangiogenic therapy.
In addition to the local sprouting of tumor microvessels from nearby vessels, endothelial precursor cells (EPC) were also found to contribute to tumor angiogenesis, by incorporating to the luminal side of the blood vessel wall (6). Although controversies arose with respect to the functional role of EPCs in tumor angiogenesis (7), other types of bone marrow–derived cells (BMDC; ref. 8), for example, hemangiocytes (9, 10), Tie-2–expressing monocytes (11), and myeloid-derived suppressor cells (MDSC; ref. 12), were found to contribute to tumor angiogenesis, by possible paracrine mechanisms.
We recently reported that acute and substantial EPC mobilization occurs in mice that were treated with either vascular disrupting agents (VDA) or chemotherapy drugs, for example, paclitaxel (13, 14). These treatments resulted in homing of EPCs to the treated tumors, where they promoted angiogenesis that was accompanied by rapid tumor cell repopulation and subsequent tumor regrowth (13, 14). We also showed that the treatment outcome was improved when the mice were treated with an antiangiogenic drug that inhibits EPC mobilization (13, 14). However, an improved outcome was not observed when the antiangiogenic drug was administered prior to chemotherapy such as gemcitabine, which does not affect mobilization of EPCs (13). The robust recruitment of EPCs to tumors induced by drugs, such as VDAs or paclitaxel, may be a consequence, at least in part, of an attempt to repair damage in the tumor vasculature caused by such drugs (15). These results further suggested that antiangiogenic drugs may act as chemosensitizing agents by inhibiting host systemic rebound angiogenesis mediated by bone marrow–derived EPCs, in response to cytotoxic drug treatment (13).
The role of BMDCs in tumors is not only limited to the induction in angiogenesis but also to metastasis. The metastatic process depends on the interaction between disseminated tumor cells (termed “seeds”) and their specific metastatic microenvironment (termed “soil”; ref. 16). Recent evidence suggests that hematopoietic progenitor cells that express the VEGF receptor-1 (VEGFR1) are crucial for creating the initial microenvironment for metastatic growth in the soil of secondary sites (17). These cells are home to distant tumor-specific premetastatic sites, where they cluster to create “premetastatic niches” for tumor cell seeding (17). EPCs have also been reported as being influential for promoting the growth of tumor metastases. Specifically, Gao and colleagues showed that EPCs are crucial regulators of the “angiogenic switch,” which mediates the shift of micrometastases to lethal macrometastases (18). Thus, the formation of metastasis-permissive niches for tumor cell seeding and their growth in other organs depends, at least in part, on several types of BMDCs, and therefore blocking their activity and/or mobilization by targeted drugs may improve treatment outcome.
Numerous molecular factors are also associated with metastasis spread. The initiation of metastases involves the invasion of tumor cells into peripheral tissue, a process which requires the crossing of several physical barriers, such as the endothelial basement membrane. Matrix metalloproteinases (MMP) have been shown to promote metastases in a growing tumor by the proteolysis of the extracellular matrix, as well as by activating signaling pathways that are important for tumor cell migration (19). MMP9, like other MMPs, belongs to a superfamily of zinc containing proteases and has been shown to associate with tumorigenesis (19). There is increasing evidence showing that tumor-associated macrophages, following their invasion into the primary tumor sites, support the motility of metastatic cancer cell extravasation (20). However, the role of MMP9 expressed by BMDCs in mice treated with chemotherapy has not been investigated.
In the current study, we hypothesized that chemotherapy may not only increase angiogenesis but also accelerate the metastatic process, the latter of which can be modulated by BMDCs, which are acutely mobilized in response to therapy. To test this hypothesis, we used non–tumor-bearing mice that were treated with maximum-tolerated dose (MTD) of either paclitaxel or gemcitabine chemotherapy, to assess the effect of the chemotherapy on the host, and the contribution of the response of host on tumor and endothelial cell activity. The results of our study reveal possible new pathways by which acute reaction of the host to some cytotoxic drugs can induce metastasis in mice.
Materials and Methods
Animal tumor models and drugs
The use of animals and experimental protocols were approved by the Animal Care and Use Committee of the Technion. Briefly, C57BL/6 and CB.17 severe-combined immunodeficient (SCID) female mice (Harlan), 8 to 10 weeks of age, were implanted with Lewis lung carcinoma (LLC) and LM2-4 breast carcinoma cells, respectively. The mice were treated with the following drugs: 50 mg/kg paclitaxel, 500 mg/kg gemcitabine, or 4 mg/kg MMP2–MMP9 inhibitor III. Detailed protocols are available in Supplementary Materials and Methods.
Cells and cell culture
Human umbilical vein endothelial cells (HUVEC) were kindly provided by Dr. Neta Ilan (Faculty of Medicine, Technion) and were cultured in gelatin-coated dishes, using a previously described protocol (21). Cells were identified as endothelial cells by the CD31 surface marker. MDA-MB-231, LLC, HT1080, MCF-7, and HEK293-T cell lines were purchased from the American Type Culture Collection and were used within 6 months of resuscitation. LM2-4 tumor cells, which were previously established from the MDA-MB-231 cell line, were kindly provided by Prof. Robert Kerbel (Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada), and were used as previously described (22). All cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum. The SCp2 murine epithelial cells were kindly provided by Prof. Israel Vlodavsky, Technion, and were cultured according to the work described by Desprez and colleagues (23). All cells were passed in culture for no more than 6 months after being thawed from authentic stocks.
Scratch wound assay
The scratch wound assay was conducted as previously described (24). Detailed protocols are available in Supplementary Materials and Methods.
Modified Boyden chamber assay
The invasion and migration properties of HUVECs and tumor cells were evaluated in either Matrigel- or fibronectin-coated Boyden chambers, using a previously described protocol (25). Detailed protocols are available in Supplementary Materials and Methods.
MMP detection by gelatin zymography
Conditioned medium from BMDCs or MDA-MB-231 cells was analyzed for MMP activity using gelatin zymography (26). Detailed protocols are available in Supplementary Materials and Methods.
Matrigel plug assay
Matrigel (0.5 mL) containing 10% plasma from treated C57BL/6 mice was injected subcutaneously into each flank of the mice (n = 4 mice per group), and the plugs were removed 10 days later. Plugs were then prepared for histologic and immunohistochemical evaluation or flow cytometric analysis.
Aortic ring assay
Aortic ring assay was conducted as previously described (10). Detailed protocols are available in Supplementary Materials and Methods.
Preparation of a single-cell suspension from the Matrigel plugs was carried out using a previously described protocol (27).
To identify the BMDC types that colonized the Matrigel plugs, single-cell suspensions of the cells from the plugs were first prepared and were then immunostained for flow cytometric analysis as described in Supplementary Materials and Methods.
The cell types in the Matrigel plugs, the tumor tissues, and the cells from various cultures were identified by immunofluorescence staining as previously described (14, 28). Detailed protocols are available in Supplementary Materials and Methods.
A chimeric mouse model with inhibited MMP9 expression in their BMDCs
Transfection of MMP9 into BMDCs was carried out as previously described for Id-1 (18). Detailed protocols are available in Supplementary Materials and Methods.
Data are presented as mean ±SEM. Statistical significance of differences was assessed by one-way ANOVA, followed by Newman–Keuls ad hoc statistical test using GraphPad Prism 4 software (GraphPad). Differences between all groups were compared with each other and were considered significant at values of P < 0.05.
The plasma from chemotherapy-treated mice induces endothelial cell invasion, migration, and vessel sprouting
Our previous studies showed that certain types of chemotherapy drugs administered to non–tumor-bearing mice can rapidly induce EPC mobilization, in part, by the overexpression of numerous factors such as granulocyte colony-stimulating factor (G-CSF) and stromal cell–derived factor 1-α (SDF-1α; refs. 13, 29). We showed that these effects stimulated angiogenesis in treated tumors and contributed to tumor regrowth. Thus, the host-derived response to chemotherapy may contribute to tumor angiogenesis and subsequent tumor regrowth (13). Therefore, we further examined the effects of paclitaxel or gemcitabine chemotherapy on the host and the effect of its response on endothelial cell behavior. To this end, we first treated non–tumor-bearing mice with MTDs of either paclitaxel or gemcitabine. After 24 hours, their plasma was collected and then used for assessing endothelial cell migration, invasion, and microvessel sprouting. Plasma from the paclitaxel-treated mice induced a significant increase in migration and invasion of endothelial cells, when compared with that caused by plasma from the vehicle-treated mice. Moreover, plasma from the gemcitabine-treated mice caused a significant increase in endothelial cell invasion but not in endothelial cell migration when compared with plasma from the vehicle-treated mice (Fig. 1A and B). Furthermore, we found that plasma from the chemotherapy-treated mice significantly increased microvessel sprouting, when compared with that caused by plasma from vehicle-treated mice as was assessed by aortic ring assay (Fig. 1C; Supplementary Fig. S1). These results provide evidence that the plasma from paclitaxel- and gemcitabine-treated mice can induce a spectrum of endothelial cell activity following chemotherapy.
The plasma of chemotherapy-treated mice promotes colonization of host cells in Matrigel plugs
To further elucidate the effect of chemotherapy on host cells, we implanted Matrigel that contained 10% plasma, which has been obtained from chemotherapy-treated mice into the flanks of C57BL/6 mice. The plugs were then assessed for the number of host cells that colonized the plugs. The number of host cells, such as the endothelial cells, in the Matrigel plugs that contained plasma from the chemotherapy-treated mice was higher than that found in Matrigel plugs that contained plasma from the vehicle-treated mice (Fig. 2A and B). We then prepared single-cell suspensions from the digested plugs to determine the numbers of both hemangiocytes and MDSCs in the implanted plugs because both are known to contribute to angiogenesis (30, 31). We found that the numbers of both hemangiocytes and MDSCs as well as CD45+ BMDCs colonizing the plugs that contained plasma from the chemotherapy-treated mice were significantly greater than those in the plugs that contained plasma of the vehicle-treated mice (Fig. 2B). These results indicate that the host reaction to chemotherapy may modulate the tumor microenvironment by recruiting host cells, some of which are hematopoietic cells known to contribute to tumor growth and angiogenesis.
BMDCs that colonized in chemotherapy-treated tumors express MMP9
We next asked whether chemotherapy promotes the migration and invasion of BMDCs into tumors. We therefore assessed the migratory properties of BMDCs from chemotherapy-treated mice using the modified Boyden chamber assay. Our results show that the extent of migration of BMDCs from the chemotherapy-treated mice was greater than that of the vehicle-treated mice (Fig. 3A).
MMPs have been reported to be important regulators of tumor cell dissemination (19), and promote the invasion of BMDCs into tumors (20, 32). Therefore, we asked whether the host response to chemotherapy may increase secretion and activation of MMPs in BMDCs and/or tumor cells, hence contributing to metastasis. To this end, we determined the levels of MMP9 in conditioned medium of BMDCs from chemotherapy-treated mice and in conditioned medium of MDA-MB-231 cells preexposed to plasma from the chemotherapy-treated mice. The levels of active MMP9 in these 2 conditioned media were at least twice as high as those in the medium in which BMDCs from the vehicle-treated mice or the MDA-MB-231 cells preexposed to plasma from the vehicle-treated mice. The levels of the proenzymatic form of MMP9 in conditioned medium of MDA-MB-231 cells preexposed to plasma from chemotherapy-treated mice was more than 10-fold higher than those levels found in MDA-MB-231 cells preexposed to plasma from the vehicle-treated mice (Fig. 3B and C).
This increase in MMP9 expression in both BMDCs and tumor cells in response to chemotherapy prompted us to investigate whether an increase in MMP9 expression also occurs in the primary tumor and its metastases following chemotherapy. To this end, 500 mm3 LLC tumor–bearing mice were treated with either paclitaxel or gemcitabine. Three days later, the mice were sacrificed, and tumors and lungs were removed for determination of the expression of MMP9 in BMDCs that colonized the primary tumor and lungs. A substantial number of MMP9-expressing CD45+ BMDCs in the tumor and lungs of the paclitaxel-treated mice, but not in the tumor and lungs of gemcitabine- or vehicle-treated mice, was observed (Fig. 3D and E; Supplementary Fig. S2A and S2B). Notably, the number of BMDCs that colonized the gemcitabine- or vehicle-treated tumors was lower than the number of BMDCs in paclitaxel-treated tumors, in agreement with our previous publication (13). Collectively, these results suggest that the host response to paclitaxel chemotherapy increases MMP9 secretion by the BMDCs that colonize the primary tumor and/or its metastases.
The plasma from chemotherapy-treated mice induces tumor cell migration and invasion
Because the plasma from chemotherapy-treated mice induced MMP9 secretion by tumor cells, we posited that chemotherapy can induce tumor cell migration and invasion, and as a result can promote the formation of new metastases. Therefore, we assessed the migratory and invasive properties of MDA-MB-231, LM2-4, LLC, and SCp2 cell lines. Plasma from paclitaxel-treated mice, and to a lesser extent plasma from gemcitabine-treated mice, enhanced the migration and invasion of all tested cells, when compared with that caused by plasma from vehicle-treated mice (Fig. 4A–D). An induction in the migration and invasion properties of MDA-MB-231 cells in the presence of plasma obtained from mice 72 hours following chemotherapy was also observed (Supplementary Fig. S3). Furthermore, we found that the motility of the MDA-MB-231 cells was greater when these cells were exposed to plasma from paclitaxel-treated mice than that caused by plasma from gemcitabine- or vehicle-treated mice in the scratch wound assay (Fig. 4E and F). To rule out the possibility that tumor-derived effects following chemotherapy can contribute to the migration and invasion properties of tumor cells in the presence of plasma from chemotherapy-treated mice, we obtained plasma from 500 mm3 LLC-bearing mice 24 hours following paclitaxel or gemcitabine chemotherapy. By using the modified Boyden chamber assay to assess migration and invasion properties of the MDA-MB-231 cells, we found that plasma from chemotherapy-treated LLC-bearing mice induced tumor cell invasion and migration, similarly to plasma obtained from non–tumor-bearing mice (Supplementary Fig. S4). Collectively, these results indicate that the host reaction to paclitaxel, and to a lesser extent to gemcitabine, can directly promote the migratory and invasive activities of tumor cells, as well as actively causing MMP9 secretion.
Plasma from paclitaxel-treated mice induces epithelial-to-mesenchymal transition
The results of recent studies have shown that epithelial-to-mesenchymal transition (EMT) in tumor cells is essential for cancer metastasis (33, 34). To examine this aspect, MCF-7 cells, frequently used for EMT studies (28), were incubated with conditioned medium of BMDCs from chemotherapy-treated mice. Forty-eight hours later, the cells were first fixed and then stained for E-cadherin (an epithelial cell marker) and vimentin (a mesenchymal cell marker) to evaluate tumor cells that undergo EMT (28). We found that EMT occurred in MCF-7 cells that were exposed to conditioned medium of BMDCs from the paclitaxel-treated mice, but it did not occur when the cells were exposed to conditioned media of BMDCs from the gemcitabine- and the vehicle-treated mice (Fig. 5). Collectively, the results provide additional support for the notion that paclitaxel can induce tumor cells to migrate, invade, and then transiently transform into mesenchymal cells as part of the metastatic process.
The effect of chemotherapy on metastases in mice
We next investigated whether chemotherapy can induce metastasis in mice. To test this possibility, C57BL/6 mice were treated with either paclitaxel or gemcitabine. After 24 hours, mice were intravenously injected with GFP+ LLC cells, and 45 days later, the mice were sacrificed and the number of metastatic GFP+ LLC cells in the lungs was determined by flow cytometry. In a parallel experiment, the survival of mice in treatment groups was assessed. We found that the number of metastatic lesions and GFP+ LLC cells in the lungs of paclitaxel-treated mice were significantly higher than those found in the lungs of gemcitabine- and vehicle-treated mice (Fig. 6A–C). In addition, the mortality rate of the paclitaxel-treated mice was higher than that of the gemcitabine- and vehicle-treated mice (Fig. 6D). Similar results were obtained in a repeat experiment where we tested whether the host response to chemotherapy was the sole cause of increased metastasis. In this experiment, GFP+ LLC cells that had been preexposed for 24 hours to plasma from the chemotherapy-treated mice were used (Fig. 6E). Furthermore, to investigate whether chemotherapy can accelerate metastases in a more clinically relevant spontaneous metastatic mouse model as well, we used the LM2-4 cells as a model of spontaneous metastases as previously shown (22). Mice bearing metastatic lesions in the lungs were treated with paclitaxel or gemcitabine administered every 21 days for 3 sequential cycles. The results in Fig. 6F show that as opposed to increased mortality rate found in mice treated with chemotherapy followed by an intravenous injection of LLC cells, mice administered with chemotherapy in multiple cycles in this spontaneous metastasis model revealed increased survival when compared with vehicle-treated mice. Collectively, the host response to paclitaxel, but not gemcitabine, can accelerate tumor metastasis in short-term rapidly administered chemotherapy but failed to do so in mice bearing spontaneous metastasis following multiple cycles of chemotherapy.
Inhibition of MMP9 can decrease metastasis following paclitaxel treatment
Our findings that the host response to paclitaxel can increase MMP9 expression in tumor cells and BMDCs prompted us to further investigate the active involvement of MMPs in metastasis following chemotherapy. We first determined the effect of an MMP inhibitor (MMPi) on the invasion of tumor cells exposed to plasma from chemotherapy-treated mice. We found that the invasion of MDA-MB-231 cells exposed to plasma from the paclitaxel-treated mice was significantly higher than that of MDA-MB-231 cells exposed to plasma from the gemcitabine-treated mice. This invasion was completely abolished by a specific MMP2–MMP9 inhibitor (Fig. 7A). We did not observe changes in the migration properties of MDA-MB-231 cells exposed to plasma from the paclitaxel- or the gemcitabine-treated mice in the presence of the MMPi (data not shown). Next, we investigated the effect of MMPi on metastasis in the paclitaxel-treated mice. First, paclitaxel or vehicle was injected into the mice, and 24 hours later, they were intravenously injected with LLC cells with or without the MMPi. Forty-five days later, we observed that mice from the MMPi monotherapy treatment group succumbed to metastases; however, survival of mice treated with MMPi and paclitaxel was remarkably extended when compared with the mice treated with paclitaxel monotherapy. The remaining mice were sacrificed, and the metastatic lesions in the lungs were counted. The number of metastases in the lungs of the combined paclitaxel and the MMPi-treated mice was smaller than that in lungs of the paclitaxel-treated mice (Fig. 7B).
An additional experiment to test the effect of inhibiting MMP9 expression in BMDCs on metastasis was carried out. MMP9 expression in BMDCs of C57BL/6 mice was inhibited by 60% by short hairpin RNA technique (Supplementary Fig. S5). Such BMDCs were transplanted into lethally irradiated mice, and after BMDC reconstitution, mice were injected with LLC cells preexposed to plasma from chemotherapy-treated mice. Mouse survival was monitored. The inhibition of MMP9 in BMDCs in mice injected with LLC cells precultured with plasma from paclitaxel-treated mice resulted in extended survival when compared with their control counterparts, which were injected with the same LLC cells (Fig. 7C). Notably, the inhibition of MMP9 in BMDCs in mice injected with LLC cells preexposed to plasma from vehicle-control mice increased mouse mortality when compared with their control counterparts (Fig. 7C). Overall, our results suggest that the inhibition of MMP9 in paclitaxel-treated mice can suppress the metastatic-promoting action of paclitaxel, but reversed therapeutic effects were observed in mice in which MMP9 expression was suppressed in BMDCs after they were injected with tumor cells preexposed to plasma from vehicle-treated mice.
Chemotherapy is one of the most common treatment modalities for cancer, and it has been used in neoadjuvant, adjuvant, and advanced metastatic disease. The results of this study provide insights into the effects of chemotherapy on the host and its reaction on tumor cells. Yamauchi and colleagues recently showed that an intravenous injection of HT1080, a human fibrosarcoma cell line which does not usually form metastases, can nevertheless promote them when injected into nude mice, which were previously treated with cyclophosphamide chemotherapy (35). We have previously reported that both VDAs and chemotherapy can induce acute mobilization of EPCs in non–tumor-bearing mice, therefore suggesting that anticancer drugs can cause host effects that promote angiogenesis and tumor regrowth (13, 14). In this study, we further investigated the effect of plasma from chemotherapy-treated mice on both host and tumor cells. We showed that plasma from chemotherapy-treated mice can induce endothelial cell invasion, migration, and microvessel sprouting. We found that MMP9 is increased in tumors and in BMDCs exposed to plasma from the chemotherapy-treated mice and showed that conditioned medium of BMDCs from paclitaxel-treated mice, but not from gemcitabine-treated mice, induced EMT of MCF-7 cells. All of these tumorigenic effects found shortly after the administration of chemotherapy markedly increased the mortality rate of mice intravenously injected with tumor cells; however, when chemotherapy was administered in multiple cycles to mice bearing spontaneous metastatic disease, a more clinically relevant tumor model, prolonged survival was actually observed in the chemotherapy-treated groups. Thus, long-term chemotherapy may overcome the tumorigenic rapid effects of the host in response to drug administration.
An interesting question that arose from this study deals with the fact that MMP9 inhibition following paclitaxel chemotherapy extended the survival of mice but the same treatment strategy in vehicle-treated mice resulted in an increased mortality rate. Hiratsuka and colleagues showed that MMP9 is induced by VEGFR1 and is expressed in both endothelial cells and macrophages in premetastatic lungs (36). Kaplan and colleagues showed that blocking VEGFR1 in premetastatic mice can inhibit metastasis growth by disrupting the premetastatic niche (17). These studies are not in line with our results, in part, due to the fact that our experiments were carried out on intravenously injected tumor cells, and therefore premetastatic niches were not formed in such mice. Nevertheless, the combination of MMPi and paclitaxel chemotherapy in mice intravenously injected with tumor cells resulted in enhanced survival when compared with mice treated with paclitaxel monotherapy. The results of our study provide additional important evidence that BMDCs can contribute to metastasis, not only in unperturbed tumors but also following acute cytotoxic drug therapy, despite the myelosuppressive effects commonly found following chemotherapy (37). The suppression of MMP9 expression in BMDCs, using genetic manipulation in a chimeric mouse model, resulted in increased survival of mice following the injection of tumor cells preexposed to plasma from chemotherapy-treated mice. Therefore, blocking or attenuating the activity of BMDCs in the primary tumor and/or its metastases may decrease the potential development of new metastases.
The host-derived factors that can contribute to metastases following chemotherapy were not studied here. It has been shown that tumor cells instigate BMDCs prior to their mobilization to distant micrometastatic sites and therefore can contribute to metastasis growth (38); in our study, we
solely tested the effects of chemotherapy that are host driven with no involvement of tumor cells. Numerous factors have been shown to be induced following therapy and can therefore promote angiogenesis and metastases (39, 40). We recently showed that an increase in plasma levels of SDF-1α and G-CSF, both of which promote the mobilization of EPCs (41), was observed in certain chemotherapy- and VDA-treated mice (13, 14). Escalating doses of sunitinib, an antiangiogenic receptor tyrosine kinase inhibitor, in non–tumor-bearing mice increased plasma levels of G-CSF, SDF-1α, stem cell factor, and osteopontin (40). Metastases were accelerated in mice that undergo short-term treatment with sunitinib (39). Do all anticancer drugs cause tumorigenic effects? It seems that the inhibition of MMP9 expression in paclitaxel-treated mice causes a reduction in metastasis, but this may not be so in combination with other anticancer drugs. Collectively, the induction of metastasis may be due, in part, to an increase in numerous host-derived factors following therapy and therefore necessitates the identification of those metastasis-accelerating factors.
In summary, this study was not designed to address the question whether chemotherapy can accelerate metastases. The clinical scenario would suggest that it does not actually do so. However, our results point out on some reasons for the explanation of why anticancer drugs may not be as effective as predicted. According to our results, it seems that some chemotherapeutic drugs, in addition to their antitumor effects, may also induce protumorigenic effects that may apparently result from the host reaction to such a therapy. These negative “side effects” of chemotherapy can promote tumor growth and metastases likely due to an upregulation of tumor-promoting factors. Therefore, adequate combinations of targeted therapies that prevent the occurrence of such responses to chemotherapy in the host may improve treatment outcome.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
S. Gingis-Velitski was supported by postdoctoral fellowships from Brain Power for Israel and Lady Davis. L. Benayoun is supported by Fine, Jacobs, and Israel Student Education Foundation studentships. This work was supported by grants from the Israel Cancer Association, Israel Science Foundation, Israel Ministry of Health, and European Commission under FP7 program (Marie Curie and European Research Commission).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
- Received February 28, 2011.
- Revision received September 19, 2011.
- Accepted September 28, 2011.
- ©2011 American Association for Cancer Research.